Literature DB >> 27795348

Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam.

Lauren K Flynt1, Michael P Veve1,2, Linoj P Samuel1, Robert J Tibbetts3.   

Abstract

Entities:  

Keywords:  ceftolozane-tazobactam

Year:  2016        PMID： 27795348      PMCID： PMC5228249          DOI： 10.1128/JCM.01920-16

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  7 in total

1.  Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  J L Burns; L Saiman; S Whittier; J Krzewinski; Z Liu; D Larone; S A Marshall; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2001-04       Impact factor: 2.803

2.  Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.

Authors:  Carlo Gagliotti; Mario Sarti; Carla Sabia; Raffaele Gargiulo; Gian Maria Rossolini; Carmelina Carillo; Carla Cassani; Antonio Paolo Cipolloni; Federica Pedna; Maria Rita Rossi; Silvia Storchi Incerti; Giovanna Testa; Claudia Venturelli; Maria Luisa Moro
Journal:  New Microbiol       Date:  2011-01-15       Impact factor: 2.479

3.  Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.

Authors:  R M Humphries; J A Hindler
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

4.  Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.

Authors:  Scott T Micek; Ann E Lloyd; David J Ritchie; Richard M Reichley; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 5.  Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.

Authors:  M H Kollef
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

Review 6.  New β-Lactamase Inhibitors in the Clinic.

Authors:  Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

7.  Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.

Authors:  Dilip Nathwani; Gowri Raman; Katherine Sulham; Meghan Gavaghan; Vandana Menon
Journal:  Antimicrob Resist Infect Control       Date:  2014-10-20       Impact factor: 4.887
  7 in total
  7 in total

1.  Verification Is an Integral Part of Antimicrobial Susceptibility Test Quality Assurance.

Authors:  Romney M Humphries; Patricia J Simner
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

Review 2.  The Continued Value of Disk Diffusion for Assessing Antimicrobial Susceptibility in Clinical Laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group.

Authors:  Romney M Humphries; Susan Kircher; Andrea Ferrell; Kevin M Krause; Rianna Malherbe; Andre Hsiung; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

3.  Development of MAST: A Microscopy-Based Antimicrobial Susceptibility Testing Platform.

Authors:  Kenneth P Smith; David L Richmond; Thea Brennan-Krohn; Hunter L Elliott; James E Kirby
Journal:  SLAS Technol       Date:  2017-08-24       Impact factor: 3.047

4.  Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Adam L Bailey; Tom Armstrong; Hari-Prakash Dwivedi; Gerald A Denys; Janet Hindler; Shelley Campeau; Maria Traczewski; Romney Humphries; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

5.  Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Authors:  Romney M Humphries; Janet A Hindler; Paul Magnano; Annie Wong-Beringer; Robert Tibbetts; Shelley A Miller
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

6.  Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Ryan K Shields; Cornelius J Clancy; A William Pasculle; Ellen G Press; Ghady Haidar; Binghua Hao; Liang Chen; Barry N Kreiswirth; M Hong Nguyen
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

7.  Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa-the EM200 study.

Authors:  J Belkhair; S Nachat; S Rouhi; H Ouassif; S Abbassi; N Soraa
Journal:  New Microbes New Infect       Date:  2021-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.